Navigation Links
Anesiva Announces Publication of Phase 3 Zingo(TM) Data in the Journal Pediatrics
Date:5/5/2008

- Zingo Demonstrates Quick, Effective Analgesia for Peripheral Venous

Access Procedures in Children Three to 18 Years of Age -(1)

SOUTH SAN FRANCISCO, Calif., May 5 /PRNewswire-FirstCall/ -- Anesiva, Inc. (Nasdaq: ANSV) announced today the publication of data in Pediatrics, the journal of the American Academy of Pediatrics, from a Phase 3 trial of Zingo(TM) (lidocaine hydrochloride monohydrate) powder intradermal injection, the company's fast-acting, topical, needle-free local anesthetic, that showed treatment with Zingo was associated with significantly less pain during intravenous (IV) line placement or venipuncture as compared to sham placebo.(1) The study is the largest trial published to date on local anesthetic use for peripheral venous access procedures in children.

"Increased use of topical local anesthetics has long been urged to reduce peripheral venous access pain in children, but use of those tools has been limited by slow onset of action," said William T. Zempsky, M.D., Associate Professor, Department of Pediatrics, University of Connecticut; Associate Director, Pain Relief Program, Connecticut Children's Medical Center, Hartford, who led the pediatric clinical trials of Zingo. "As demonstrated in the Phase 3 trial, Zingo's rapid action is a leap forward in the control of peripheral venous access pain management for children."

More than 18 million children undergo venous access procedures, including blood draws and IV insertions, in U.S. hospitals each year.(2) In addition to the commonality of venous access procedures, they are also a source of pain for children.(3) According to a study published in the journal Pediatric Nursing, IV insertions and blood draws are the most frequently reported pai
'/>"/>

SOURCE Anesiva, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Anesiva Announces Pivotal Phase 3 Clinical Trial of Adlea(TM) for Reducing Post-Surgical Pain Following Total Knee Replacement
2. Anesiva Commences Phase 3 Clinical Trial of Adlea(TM) for Reducing Post-Surgical Pain Following Bunionectomy
3. Anesiva Announces Pivotal Phase 3 Trial of Zingo(TM) Meets Primary Endpoint and Significantly Reduces Venous Access Pain in Adults
4. Anesiva Defines Regulatory Pathway for Adlea with FDA
5. Anesiva Initiates Phase 2 Trial with Adlea(TM) for Pain Relief Following Total Hip Replacement Surgery
6. Anesiva Initiates New Phase 2 Trial of Adlea(TM) for Pain Relief Following Knee Replacement Surgery
7. Anesiva Completes Enrollment in Phase 3 Clinical Trial of Zingo(TM) to Treat Pain Associated With Venous Access Procedures in Adults
8. ISTA Pharmaceuticals Announces New Phase III Clinical Findings to Support Bepreve NDA Filing
9. Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) GENTAMICIN TOPICAL for the Prevention of Diabetic Foot Infections
10. Medarex Announces Presentations at Annual Meeting of the American Society of Clinical Oncology
11. Alexza Announces Positive Phase 1 Results With AZ-007 (Staccato(R) Zaleplon)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... Aug. 28, 2015  Delays in the launch ... slow down the decision-making process, resulting in missed ... critical for biopharmaceutical companies to develop a tactical ... for quicker and more meaningful insights. ... LLC, nearly three-quarters of benchmarked study participants use ...
(Date:8/28/2015)... According to a new market ... Prostate) Type (Protein & Genetic Biomarkers) Profiling Technology (Proteomics, ... Geography - Global Forecast to 2020", published by MarketsandMarkets, ... 17,689.0 Million USD by 2020 at a CAGR of ... Browse 191 Tables and 38 F ...
(Date:8/28/2015)... -- Research and Markets ( http://www.researchandmarkets.com/research/686gwf/investigation ... Report on China,s Bevacizumab Market ,2010-2019" report to ... trade name of Avastin, bevacizumab injection is the first ... was approved by CFDA to treat metastatic colorectal cancer. ... all come from Roche and its subsidiary Genectech. ...
Breaking Medicine Technology:Expediting the Pharmaceutical Market Research Process for Faster Insights 2Cancer Biomarkers Market Worth 17,689.0 Million USD by 2020 2Cancer Biomarkers Market Worth 17,689.0 Million USD by 2020 3Cancer Biomarkers Market Worth 17,689.0 Million USD by 2020 4Cancer Biomarkers Market Worth 17,689.0 Million USD by 2020 5Investigation Report on China's Bevacizumab Market 2015-2019 2
... Radiologists are using a new minimally,invasive procedure to ... reduces pain from calcific tendonitis of,the rotator cuff ... at the annual meeting of the Radiological Society ... successful and inexpensive therapy for tendon,calcifications," said Luca ...
... releases data on minimally invasive alternative to ... ... Bio-Surfaces, Inc. (ABS),announced today the availability of OrthoGlide Medial Knee ... of enrollment in the,OrthoGlide clinical study was presented on November ...
Cached Medicine Technology:Minimally Invasive Treatment Reduces Shoulder Pain From Tendonitis 2Minimally Invasive Treatment Reduces Shoulder Pain From Tendonitis 3Clinical Data Presented on OrthoGlide(R) Medial Knee Implant 2
(Date:8/31/2015)... Pittsburgh, PA (PRWEB) , ... August 31, 2015 ... ... television than their peers may be at a greater risk for injury, potentially ... risk-taking behaviors, a University of Pittsburgh Graduate School of Public Health analysis discovered. ...
(Date:8/31/2015)... ... August 31, 2015 , ... Kognito , a ... their competencies in managing challenging conversations, announced today that Glenn Albright, Ph.D., the ... of Excellence for Psychological Health and Traumatic Brain Injury (DCoE) Summit taking ...
(Date:8/31/2015)... ... August 31, 2015 , ... On Saturday, May 30th, 2015, Best ... Adams County Fairgrounds in Mendon, IL. The purpose behind this concert was to raise ... neighboring town, Quincy. Best Drug Rehabilitation’s sponsorship of “Music with a Mission” helped with ...
(Date:8/31/2015)... , ... August 31, 2015 , ... ... e-Spirit to future-proof its content management system (CMS) and make website updates quicker ... Sports in making the websites of the Bundesliga (the German equivalent of the ...
(Date:8/31/2015)... ... 2015 , ... “My mother and husband use oxygen therapy and the tubing ... there could be a comfortable way to prevent the irritation, so I invented this.” ... a more secure way to anchor the cannula tubing used in oxygen therapy and ...
Breaking Medicine News(10 mins):Health News:Television Viewing Linked to Higher Injury Risk in Hostile People 2Health News:Television Viewing Linked to Higher Injury Risk in Hostile People 3Health News:Kognito’s Glenn Albright to Present at DCoE Summit 2Health News:2015 "Music With A Mission" Sponsor Best Drug Rehabilitation Releases Artist Compilation Video 2Health News:2015 "Music With A Mission" Sponsor Best Drug Rehabilitation Releases Artist Compilation Video 3Health News:On the Ball with FirstSpirit: German Soccer League (DFL Digital Sports) Opts for e-Spirit’s CMS 2Health News:InventHelp® Inventor Designs Nasal Cannula Ear Protector (AVZ-1217) 2
... Babies born to HIV-positive mothers and given the antiretroviral ... to prevent infection via breast-feeding are at high risk ... a team of researchers report. But the investigators highlight ... mother-to-child HIV transmission in breast-fed infants. , ...
... Corporation (NYSE: CBM ) is pleased ... Chief Executive Officer, will be presenting at the ... 9:00 a.m. PST at the Westin St. Francis, ... http://www.newscom.com/cgi-bin/prnh/20000613/CAMBREXLOGO )A live webcast of the presentation ...
... Jan. 5 Volcano Corporation,(Nasdaq: VOLC ), ... for the diagnosis and treatment of coronary and peripheral ... January 6, to,discuss its acquisition of Axsun Technologies, Inc., ... The teleconference call and webcast will begin ...
... Few things are as tiresome as house hunting and ... down pat. Tripping nimbly from one abode to another, ... than the original tumor. Although little has been known ... down roots, researchers at the Stanford University School of ...
... the U.S. each year have been exposed to alcohol or illicit ... the National Center on Substance Abuse and Child Welfare. If removed ... in foster care longer, and chances are very low that they ... led by Joseph P. Ryan, a faculty member in the School ...
... with Operation Smile to See the Difference, Make a ... through March 2009, Crest and Oral-B are encouraging people across the ... while also making a difference in children,s smiles worldwide. When ... difference in their smile. People can also make a ...
Cached Medicine News:Health News:Prolonged nevirapine in breast-fed babies prevents HIV infection but leads to drug-resistant HIV 2Health News:Prolonged nevirapine in breast-fed babies prevents HIV infection but leads to drug-resistant HIV 3Health News:Reminder: Volcano Corporation Schedules Conference Call, Webcast to Discuss Axsun Transaction 2Health News:'Relocation' plan of metastatic cancer cells uncovered by Stanford researchers 2Health News:'Recovery coaches' effective in reducing number of babies exposed to drugs 2Health News:'Recovery coaches' effective in reducing number of babies exposed to drugs 3Health News:Crest and Oral-B Challenge America to See The Difference in Their Smile and Make A Difference in Children's Smiles Around the World 2Health News:Crest and Oral-B Challenge America to See The Difference in Their Smile and Make A Difference in Children's Smiles Around the World 3Health News:Crest and Oral-B Challenge America to See The Difference in Their Smile and Make A Difference in Children's Smiles Around the World 4
Low Profile Design for Precise Anchor Placement...
... utilizes a suprapubic approach to treat ... urethral hypermobility and/or intrinsic sphincter deficiency ... needles and a self-fixating sling with ... for intra-operative tension refinement without mesh ...
... The Uretex® Trans-Obturator ... excellent tension-free, self-anchoring support ... The polypropylene mesh maintains ... flat placement under the ...
... Delivers the durability of natural ... benefits of ingrowth and natural ... or exceeds all applicable state ... Allograft Tissue also reduces OR ...
Medicine Products: